AstraZeneca seems to have new ambitions.

Read: AstraZeneca to buy Gilead in hundreds of billionsOn the afternoon of June 7th,, a message that AstraZeneca was trying to acquire Gilead began to paint the screenThe move comes from a new Bloomberg report that people familiar with the matter said AstraZeneca contacted Gilead last month to seek possible cooperationPeople familiar with the matter added that while Gilead had discussed the idea with financial advisers, it had not yet been decided and no formal talks had been held between the two companiesif the news is true and a final deal is reached, it will surpass last year's $74 billion acquisition of New base by BMS, making it the largest pharmaceutical deal in historya spokesman forAstraZeneca said the company would not comment on the speculationGilead has yet to respondtwo pharmaceutical giants, AstraZeneca, which is now worth $140bn, is the UK's largest drugmaker, dealing in a range of fields such as cancer and cardiovascular diseaseGilead, with a market capitalisation of $96 billion, has gained global fame this year with Redsewefor the moment, only two people may have the most say on the dealOne is Pascal Soriot, AstraZeneca's chief executive, and the other is Cadrede chief executive Dan O'DayCoincidentally, they have a delicate relationship, having worked for Roche, another pharmaceutical giantPascal Soriot, a former veterinarian with an MBA, has many years of experience in the pharmaceutical industryPreviously, Pascal Soriot worked as an executive at Roche Pharmaceuticals and led to Roche's full acquisition of GenentechPascal Soriot became AstraZeneca's CEO in 20122014, Soriot successfully blocked Pfizer's $120 billion bid to buy AstraZeneca, and his goal was to turn the company around on its own, and it attracted a lot of attention, in response to the deal rumors, there are also comments from netizens: AstraZeneca once rejected the pursuit of others (Pfizer), and now began to pursue others (Gilead)Dan O'Day will be Gilead's CEO from March 2019He joined Roche Pharmaceuticals USA as early as 1987 and has served at Roche for nearly 30 years, spanning three decades of leadership positions in North America, Asia Pacific and EuropeDaniel O'Day joined Gilead for the third year in a row, with revenues of $22.127 billion in 2018 down 15.2 percent from a year earlier, down from the top pharmaceutical Top 10 list in the world since 2014To get Gilead back on the track, Daniel O'Day led Gilead in a top-down transformation from restructuring its executive team to developing pipelinesIt's worth noting that Daniel O'Day's elevation to chief financial officer, Andrew Dickinson, shortly after he took office, is not hard to see as "mergers and co-operations may be critical to Gilead's asset allocation strategy"in the global pharmaceutical market, AstraZeneca has been in full swing for nearly a yearIn 2019, AstraZeneca entered the global TOP10 for the first time with $24.384 billion in revenueAnd its heavyweight drug majors are growing rapidly, and last year AstraZeneca was named The Pharmaceutical Company of the Year in 2019 by BioDivePharma, a foreign biopharmaceutical websiteand Gilead has seen its third consecutive year of decline since 2016, and in 2018 it has even fallen out of the top global pharmaceutical Top10 list since 2014Gilead's full-year revenue for 2019 was $22,449 million, up 1.5 percent from a year earlier, and while the decline has stopped, It is urgent to find its next cash cow product due to the recent decline in performance of its core drug, hepatitis Cbut there are also questions about the timing of the dealIf the new crown vaccine, developed in partnership with Oxford University, is successful, it could have a potential impact on AstraZeneca's share price, and it won't have to pursue record deals, especially when travel restrictions are limited and face-to-face conversations are not convenientGilead has also been a pioneer in COVID-19 therapy, and its Redseweantiviral is the first drug to improve patients with COVID-19, and has been approved for emergency use in PATIENTs with COVID-19 in countries such as the United States and South KoreaRedseyway's annual sales are estimated to exceed $7 billion by 2022 if the government seeks to stockpile the drug in response to future crowns became a landmark year in the history of biopharmaceutical mergers and acquisitions in 2019, following BMS's $74 billion acquisition of New Age and AbbVie's $63 billion acquisition of Al-Jian Will we witness a new history in 2020? See